WO2011101829A3 - A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it - Google Patents

A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it Download PDF

Info

Publication number
WO2011101829A3
WO2011101829A3 PCT/IB2011/050717 IB2011050717W WO2011101829A3 WO 2011101829 A3 WO2011101829 A3 WO 2011101829A3 IB 2011050717 W IB2011050717 W IB 2011050717W WO 2011101829 A3 WO2011101829 A3 WO 2011101829A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusidic acid
sodium fusidate
betamethasone dipropionate
miconazole nitrate
corticosteroid
Prior art date
Application number
PCT/IB2011/050717
Other languages
French (fr)
Other versions
WO2011101829A2 (en
Inventor
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Kausik Ghosh
Sankar Haridas
Original Assignee
Sulur Subramaniam Vanangamudi
Madhavan Srinivasan
Neelakandan Narayanan Chulliel
Kausik Ghosh
Sankar Haridas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulur Subramaniam Vanangamudi, Madhavan Srinivasan, Neelakandan Narayanan Chulliel, Kausik Ghosh, Sankar Haridas filed Critical Sulur Subramaniam Vanangamudi
Publication of WO2011101829A2 publication Critical patent/WO2011101829A2/en
Publication of WO2011101829A3 publication Critical patent/WO2011101829A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a dermaceutical cream containing Betamethasone Dipropionate as a corticosteroid, an antifungal agent in the form of Miconazole Nitrate and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention has greater shelf-life stability and the finer particle size of the API than the conventional creams containing Fusidic acid. The cream of the present invention contains Fusidic acid as the API that has been formed in situ from Sodium Fusidate, Betamethasone Dipropionate and Miconazole Nitrate, in a cream base comprising a preservative, an acid, a co-solvent, emulsifiers and a waxy material along with water, preferably purified water.
PCT/IB2011/050717 2010-02-22 2011-02-22 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it WO2011101829A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN59MU2010 2010-02-22
IN59/MUM/2010 2010-02-22

Publications (2)

Publication Number Publication Date
WO2011101829A2 WO2011101829A2 (en) 2011-08-25
WO2011101829A3 true WO2011101829A3 (en) 2011-12-29

Family

ID=44483421

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2011/050717 WO2011101829A2 (en) 2010-02-22 2011-02-22 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it

Country Status (1)

Country Link
WO (1) WO2011101829A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012049545A1 (en) * 2010-10-12 2012-04-19 Sulur Subramaniam Vanangamudi A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045645A1 (en) * 1999-12-23 2001-06-28 Ivrea, Inc. Chitosan biopolymer for the topical delivery of active agents
WO2009063493A2 (en) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210840A (en) 1984-01-18 1987-05-29 Johnson & Johnson Baby Prod Composition comprising synergistic combination of miconazole nitrate and zinc oxide
US5461068A (en) 1993-09-29 1995-10-24 Corwood Laboratories, Inc. Imidazole derivative tincture and method of manufacture
CA2223747A1 (en) 1995-06-07 1996-12-19 Taisho Pharmaceutical Co., Ltd. Antifungal compositions
US6645473B2 (en) 2000-07-24 2003-11-11 Diana L. Hauan Combination tanning and antifungal topical system for treating tinea versicolor
NL1030438C2 (en) 2005-11-16 2007-05-21 Happy Foot Composition with antifungal properties, use and method.
BRPI0707367A2 (en) 2006-02-02 2011-05-03 Leo Pharma As pharmaceutical composition, use of a composition, and method of preventing or treating a dermal disease or condition of the skin or mucosa
CN100462075C (en) 2006-09-20 2009-02-18 西北农林科技大学 Nanometer miconazole nitrate emulsion medicine and its prepn process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045645A1 (en) * 1999-12-23 2001-06-28 Ivrea, Inc. Chitosan biopolymer for the topical delivery of active agents
WO2009063493A2 (en) * 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALSARRA ET AL: "Chitosan topical gel formulation in the management of burn wounds", INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, ELSEVIER BV, NL, vol. 45, no. 1, 1 July 2009 (2009-07-01), pages 16 - 21, XP026116180, ISSN: 0141-8130, [retrieved on 20090402], DOI: 10.1016/J.IJBIOMAC.2009.03.010 *
RAMSAY C A ET AL: "The treatment of atopic dermatitis with topical fusidic acid and hydrocortisone acetate", JEADV. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 7, no. SUPPL. I, 1 July 1996 (1996-07-01), pages S15 - S22, XP002582785, ISSN: 0926-9959, [retrieved on 20021011], DOI: 10.1016/0926-9959(96)00032-3 *
RAVI KUMAR M N V: "A review of chitin and chitosan applications", REACTIVE & FUNCTIONAL POLYMERS, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 46, no. 1, 1 November 2000 (2000-11-01), pages 1 - 27, XP004224437, ISSN: 1381-5148, DOI: 10.1016/S1381-5148(00)00038-9 *

Also Published As

Publication number Publication date
WO2011101829A2 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
EP3458074A4 (en) COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
WO2012151248A3 (en) FORMULATION FOR ANTI-α4β7 ANTIBODY
WO2011156030A3 (en) High oil-content emollient aerosol foam compositions
MX354480B (en) Foamable benzoyl peroxide compositions for topical administration.
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2009063493A3 (en) Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
WO2011115700A3 (en) Emollient foams for treatment of seborrheic dermatitis
WO2014030770A3 (en) Copolymer having carbosiloxane dendrimer structure and hydrophilic group
WO2011107522A3 (en) Foam formulations containing at least one triterpenoid
WO2011156566A3 (en) Chemically stabilized anti-dandruff compositions for use in personal care compositions
WO2013175221A3 (en) Composition
WO2014121048A3 (en) Topical compositions and methods for making and using same
WO2012070804A3 (en) Cosmetic composition containing an oleanolic acid
WO2015171460A3 (en) Formulations of cyclophosphamide liquid concentrate
WO2011100975A3 (en) Stabilized tacrolimus composition
WO2010109425A3 (en) A medicinal steroids cream and a process to make it
WO2013079605A3 (en) Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
WO2010057214A3 (en) Nanoparticles and porous particles and methods of making the same
WO2014007770A3 (en) Inhalation compositions comprising corticosteroid and sorbitol
WO2014091196A3 (en) Solid cosmetic composition comprising a vegetable butter having dispersed therein gas bubbles
WO2012173458A3 (en) Stabilized active materials contained in plant cells and method for preparing same
MX2019008865A (en) Solid preparation comprising tofogliflozin and method for producing same.
JP2015157874A5 (en)
WO2011101828A8 (en) A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and betamethasone, and a process to make it
WO2011101829A3 (en) A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer, a corticosteroid - betamethasone dipropionate and an antifungal agent - miconazole nitrate, and a process to make it

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11712011

Country of ref document: EP

Kind code of ref document: A2